FIG A1.

Somatic variant landscape at baseline and 9 weeks. Pretreatment (left panel) and on-treatment (right panel) ctDNA analysis showing nonsynonymous variants (green), indels (golden brown), or both (red) detected in each gene for the 62 patients with at least one baseline mutation identified. Number of variants detected in each patient is represented by the height of the bars and patients are arranged in increasing order. Rows indicate assessment of response at 6 months with DCB (green), NDB (beige), and one patient without a 6-month assessment (dark gray); treatment with pembrolizumab monotherapy (gold) or pembrolizumab plus chemotherapy (light purple); smoking status with current (dark purple), former (teal), and never smokers (light gray); and PD-L1 status with PD-L1 > 50% (dark blue). DCB, durable clinical benefit; NDR, no durable benefit; PD-L1, programmed death ligand 1.